Literature DB >> 11680576

Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition.

M R Kraus1, A Schäfer, H Csef, H Faller, H Mörk, M Scheurlen.   

Abstract

Tolerance of interferon-a therapy for hepatitis C is often poor and medication is expensive. Compliance with diagnostic procedures and, even more important, with medical treatment is obviously critical to minimize the rate of dropouts and to maximize cost efficiency. Moreover, a good concordance with scheduled follow-ups is important for early recognition and treatment of interferon-associated side effects. Therefore, we investigated psychiatric symptoms, interpersonal problems, different modes of acquisition, and sociodemographic factors in HCV-infected patients as possible predictor variables of good versus poor compliance. In a longitudinal study, 74 patients with chronic hepatitis C (CHC) who fulfilled the criteria for treatment with interferon (IFN)-alpha-2b with or without ribavirin were investigated prospectively to identify those at risk for poor compliance during IFN medication. To assess predictive factors, we used both IIP-C (Inventory of Interpersonal Problems) and SCL-90-R (Symptom Check List 90 Items Revised) as psychometric instruments. Sociodemographic and somatic variables as well as compliance during IFN therapy were also evaluated. Poor compliance before or during medication was demonstrated by 23% (N = 17) of HCV patients. Sociodemographic factors and mode of acquisition, particularly former intravenous drug (IVD) abuse were not significantly linked with compliance. Logistic regression analysis demonstrated that the subgroup of patients with compliance problems was best identified by both pretherapeutic psychiatric symptoms and interpersonal problems. Predictive value was best and significant for anger-hostility (P = 0.009), intrusive (P = 0.014), depression (P = 0.015), and phobic anxiety (P = 0.049). Adopting this statistical prediction model, sensitivity was 47.1%, but specificity reached 98.3%. In total, 86.5% of cases were classified correctly. In situations of unclear indication for IFN therapy, psychological variables assessment of before the beginning of treatment may represent an additional decision-making factor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11680576     DOI: 10.1023/a:1011973823032

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  19 in total

1.  Compliance becomes concordance.

Authors:  P D Mullen
Journal:  BMJ       Date:  1997-03-08

2.  [Determinants of high risk illness behavior in patients with bronchial asthma].

Authors:  W Wöller; J Kruse; N Schmitz; B Richter
Journal:  Psychother Psychosom Med Psychol       Date:  1998 Mar-Apr

3.  Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy.

Authors:  P W Choo; C S Rand; T S Inui; M L Lee; E Cain; M Cordeiro-Breault; C Canning; R Platt
Journal:  Med Care       Date:  1999-09       Impact factor: 2.983

4.  Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment.

Authors:  D C Mohr; D E Goodkin; W Likosky; N Gatto; L K Neilley; C Griffin; B Stiebling
Journal:  Mult Scler       Date:  1996-12       Impact factor: 6.312

5.  [Acceptance of, compliance with and tolerance to antiretroviral treatment in patients with human immunodeficiency virus infection].

Authors:  H Knobel; C Serrano; P Hernández; M Pavesi; A Díez
Journal:  An Med Interna       Date:  1997-09

6.  Implications of directly observed therapy in tuberculosis control measures among IDUs.

Authors:  R Curtis; S R Friedman; A Neaigus; B Jose; M Goldstein; D C Des Jarlais
Journal:  Public Health Rep       Date:  1994 May-Jun       Impact factor: 2.792

7.  Medication compliance in patients with chronic schizophrenia: implications for the community management of mentally disordered offenders.

Authors:  J C Duncan; R Rogers
Journal:  J Forensic Sci       Date:  1998-11       Impact factor: 1.832

8.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

9.  The psychological factors associated with poor compliance with treatment in asthma.

Authors:  C M Bosley; J A Fosbury; G M Cochrane
Journal:  Eur Respir J       Date:  1995-06       Impact factor: 16.671

10.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

View more
  20 in total

Review 1.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

2.  The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.

Authors:  Tarek Hassanein; Mitchell L Shiffman; Nizar N Zein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-06

3.  Effect of alpha 2b interferon on inducement of mIL-2R and treatment of HCV in PBMC from patients with chronic viral hepatitis C.

Authors:  Jian Wang; Gui-Ju Xiang; Bing-Xiang Liu
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

4.  Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems.

Authors:  David Nunes; Richard Saitz; Howard Libman; Debbie M Cheng; John Vidaver; Jeffrey H Samet
Journal:  Alcohol Clin Exp Res       Date:  2006-09       Impact factor: 3.455

5.  Management of Adverse Events During the Treatment of Chronic Hepatitis C Infection.

Authors:  Douglas L Nguyen; Timothy R Morgan
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-04

6.  Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C.

Authors:  Michael-R Kraus; Arne Schäfer; Herbert Csef; Michael Scheurlen
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

7.  The cost-effectiveness of telestroke in the treatment of acute ischemic stroke.

Authors:  R E Nelson; G M Saltzman; E J Skalabrin; B M Demaerschalk; J J Majersik
Journal:  Neurology       Date:  2011-09-14       Impact factor: 9.910

8.  Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.

Authors:  Charles L Raison; Andrey S Borisov; Sherry D Broadwell; Lucile Capuron; Bobbi J Woolwine; Ira M Jacobson; Charles B Nemeroff; Andrew H Miller
Journal:  J Clin Psychiatry       Date:  2005-01       Impact factor: 4.384

Review 9.  Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management.

Authors:  Jennifer M Loftis; Annette M Matthews; Peter Hauser
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 10.  Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015.

Authors:  Salvatore Monaco; Sara Mariotto; Sergio Ferrari; Massimiliano Calabrese; Gianluigi Zanusso; Alberto Gajofatto; Domenico Sansonno; Franco Dammacco
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.